New-Born Screening Market Research Report – Forecast to 2023

New-Born Screening Market Research Report – Forecast to 2023

ID: MRFR/HC/5099-HCRR | November, 2018 | Region: Global | 85 pages | Half-Cooked Research Reports

Global New-Born Screening Market: By Technology (Electrophoresis, DNA-Based Assays, Electrophoresis), Test type (Dry Blood Spot, Urine Test), Products (Instruments, Reagents, and Assay Kits), and End Users (Hospitals and Others)—Global Forecast till 2023


Market Scenario


The global new-born screening market is expected to register a significant growth of 10.5% CAGR during the forecast period (2018–2023).


New-born Screening or Neonatal Screening is a technique used to identify harmful developmental or metabolic disorders, genetic which may result in mental retardation or death if not detected. The screening process includes a series of tests which are crucial for early detection, diagnosis, and health management, to prevent overall disability and prevent the death of a child. These assessments are performed shortly after the baby is born and detected for genetic, developmental and metabolic disorders in new-born babies.


The various government initiatives along with raising awareness of the screening benefits boost the growth of the market. Numerous technological innovations in the devices along with an expanding profile of new-born diseases foster the growth of the market. Increasing incidences of critical congenital heart defects fuel the growth of the critical congenital heart diseases (CCHD) screening market. Nevertheless, the absence of infrastructure along with various socio-economic restraints might hinder the growth of the market. Screening of genetic disorders and various Asian regions offers significant growth opportunities in the market. Next-generation sequencing (NGS) is an emerging technology in the newborn screening market. The heavy cost of automation technology along with the rigid competition presented by small players is a key market challenge that needs to be overcome by key market players to grow in the market. Additionally, the lack of combined new-born screening policies and procedures across the globe is a key market challenge.


Segmentation


The global new-born screening market has been segmented on the basis of technology, test type, product and end users.


On the basis of technology, the market has been classified as tandem mass spectrometry (TMS), electrophoresis, immunoassays, and enzymatic assays, DNA-based assays, hearing screening technology, pulse oximetry screening technology.


On the basis of test type, the market has been classified as a dry blood spot test, hearing screening test, critical congenital heart diseases (CCHD) test, urine test, and others.


On the basis of products, the market has been classified as instruments and reagents and assay kits. The instruments have been segmented into the mass spectrometer, laparoscope, retinoscope, ultrasound machine, new-born hearing screening instruments, pulse oximeters. The new-born hearing screening instruments segment has been further segmented into hearing screening devices and hearing screening accessories.


On the basis of end users, the market has been classified as hospitals, maternity & specialty clinics, diagnostic centers, and others.


On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.


The European new-born screening market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The new-born screening market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The new-born screening market in the Middle East and Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Global New-Born Screening Market Share, by Region, 2017 (%)


New-Born Screening Market


Source: MRFR Analysis


In the new-born screening market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, the rise in awareness, the rise in growth of the healthcare sector, and due to favorable compensation setting for many surgical procedures. According to the United States government, the new-born Screening Quality Assurance Program at the Centers for Disease Control and Prevention (CDC) is sponsored at USD 8.4 million and for the Heritable Disorders program at Health Resources and Services Administration (HRSA) is backed up at USD 13.88 million. The most common new-born screening tests in the US include sickle cell disease, phenylketonuria, hypothyroidism, and galactosemia,


The European market is expected to hold the second largest market share. The market growth in this region can be attributed due to the rising frequency and awareness of neonatal disorders, due to the advancement in the healthcare industry and expanded government support are boosting the European market. The increasing government funding in Europe for new-born screening within a national health service or a legal health insurance is anticipated to drive the new-born screening market growth in Europe.


The Asia-Pacific market is expected to be the fastest growing segment in the near future because of the high rate of development in the healthcare industry, increasing prospects for new marketers and rising government activity for the control of new-born diseases. Key challenges faced by the overall Asia-Pacific new-born screening market includes issues such as socio-economic barriers for the execution of new-born child screening and lack of proper healthcare infrastructure for new-born babies in some of its developing countries.


The market in the Middle East and Africa is expected to account for the smallest share of the global new-born screening market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.


Key Players


Some of the key players in the global new-born screening market are AB Sciex LLC (A Subsidiary of Danaher Corporation), Perkinelmer, Inc., Waters Corporation, Natus Medical Incorporated, Masimo Corporation, Agilent Technologies Inc., Bio-Rad Laboratories, Inc., Covidien PLC, GE Healthcare (A Subsidiary of General Electric Company), Trivitron Healthcare, ZenTech S.A and Others.


Global New-Born Screening Market, by Technology



  • Tandem mass spectrometry (TMS)

  • Electrophoresis

  • Immunoassays and enzymatic assays

  • DNA-based assays

  • Hearing screening technology

  • Pulse oximetry screening technology


Global New-Born Screening Market, by Test type



  • Dry blood spot test

  • Hearing screening test

  • Critical congenital heart diseases (CCHD) test

  • Urine test

  • Others


Global New-Born Screening Market, by Products



  • Instruments

  • Mass spectrometer

  • Laparoscope

  • Retinoscope

  • Ultrasound machine

  • New-Born hearing screening instruments

  • Hearing screening devices

  • Hearing screening accessories

  • Pulse oximeters

  • Reagents and assay kits


Global New-Born Screening Market, by End-Users



  • Hospitals

  • Maternity and specialty clinics

  • Diagnostic centers

  • Others


Global New-Born Screening Market, by Region


Americas


  • North America

  • US

  • Canada

  • South America


Europe


  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe


Asia-Pacific


  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific


Middle East & Africa


  • Middle East

  • Africa

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global New-born Screening, by Technology

6.1 Introduction

6.2 Tandem mass spectrometry (TMS)

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.3 Electrophoresis

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.4 Immunoassays and enzymatic assays

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.5 DNA-based assays

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.6 Hearing screening technology

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023



6.7 Pulse oximetry screening technology

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

Chapter 7. Global New-born Screening, by Test type

7.1 Introduction

7.2 Dry blood spot test

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

7.3 Hearing screening test

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

7.4 Critical congenital heart diseases (CCHD) test

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

7.5 Urine test

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

7.6 Others

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

Chapter 8. Global New-born Screening, by Products

8.1 Introduction

8.2 Instruments

8.2.1 Mass spectrometer

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

8.2.2 Laparoscope

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

8.2.3 Retinoscope

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

8.2.4 Ultrasound machine

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

8.2.5 New-born hearing screening instruments

8.2.5.1 Hearing screening devices

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

8.2.5.2 Hearing screening accessories

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

8.2.6 Pulse oximeters

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

8.3 Reagents and assay kits

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023



Chapter 9. Global New-born Screening, by End Users

9.1 Introduction

9.2 Hospitals

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

9.3 Maternity and specialty clinics

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

9.4 Diagnostic centers

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

9.6 Others

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

Chapter 10. Global New-born Screening, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.4.6 Rest of Asia-Pacific

10.5 Middle East & Africa

10.5.1 Middle East

10.5.2 Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

Chapter 12. Company Profiles

12.1 AB Sciex LLC (A Subsidiary of Danaher Corporation)

12.1.1 Company Overview

12.1.2 Technology Overview

12.1.3 Financials Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 Perkinelmer, Inc.

12.2.1 Company Overview

12.2.2 Technology Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Waters Corporation

12.3.1 Company Overview

12.3.2 Technology Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Natus Medical Incorporated

12.4.1 Company Overview

12.4.2 Technology/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Masimo Corporation

12.5.1 Company Overview

12.5.2 Technology Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 Agilent Technologies Inc.

12.6.1 Company Overview

12.6.2 Technology Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Bio-Rad Laboratories, Inc.

12.7.1 Overview

12.7.2 Technology Overview

12.7.3 Financial Overview

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Covidien PLC

12.8.1 Overview

12.8.2 Technology/ Technology Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 GE Healthcare (A Subsidiary of General Electric Company)

12.9.1 Overview

12. 9.2 Technology Overview

12. 9.3 Financials

12. 9.4 Key Developments

12. 9.5 SWOT Analysis

12.10 Trivitron Healthcare

12.10.1 Overview

12.10.2 Technology Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 ZenTech S.A

12.11.1 Overview

12.11.2 Technology Overview

12.11.3 Financials

12.11.4 Key Developments

12.11.5 SWOT Analysis

12.12 Others

12.12.1 Overview

12.12.2 Technology Overview

12.12.3 Financials

12.12.4 Key Developments

12.12.5 SWOT Analysis

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s Viewpoint

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Predictions for the Newborn Screening Industry

Chapter 14. Appendix

LIST OF TABLES

Table 1 Global New-born Screening Synopsis, 2018–2023

Table 2 Global New-born Screening Estimates and Forecast, 2018–2023 (USD Million)

Table 3 Global New-born Screening, by Region, 2018–2023 (USD Million)

Table 4 Global New-born Screening, by Technology, 2018–2023 (USD Million)

Table 5 Global New-born Screening, by Test type, 2018–2023 (USD Million)

Table 6 Global New-born Screening, by Products, 2018–2023 (USD Million)

Table 7 Global New-born Screening, by End Users, 2018–2023 (USD Million)

Table 8 North America: New-born Screening, by Technology, 2018–2023 (USD Million)

Table 9 North America: New-born Screening, by Test type, 2018–2023 (USD Million)

Table 10 North America: New-born Screening, by Products, 2018–2023 (USD Million)

Table 11 North America: New-born Screening, by End Users, 2018–2023 (USD Million)

Table 12 US: New-born Screening, by Technology, 2018–2023 (USD Million)

Table 13 US: New-born Screening, by Test type, 2018–2023 (USD Million)

Table 14 US: New-born Screening, by Products, 2018–2023 (USD Million)

Table 15 US: New-born Screening, by End Users, 2018–2023 (USD Million)

Table 16 Canada: New-born Screening, by Technology, 2018–2023 (USD Million)

Table 17 Canada: New-born Screening, by Test type, 2018–2023 (USD Million)

Table 18 Canada: New-born Screening, by Products, 2018–2023 (USD Million)

Table 19 Canada: New-born Screening, by End Users, 2018–2023 (USD Million)

Table 20 South America: New-born Screening, by Technology, 2018–2023 (USD Million)

Table 21 South America: New-born Screening, by Test type, 2018–2023 (USD Million)

Table 22 South America: New-born Screening, by Products, 2018–2023 (USD Million)

Table 23 South America: New-born Screening, by End Users, 2018–2023 (USD Million)

Table 24 Europe: New-born Screening, by Technology, 2018–2023 (USD Million)

Table 25 Europe: New-born Screening, by Test type, 2018–2023 (USD Million)

Table 26 Europe: New-born Screening, by Products, 2018–2023 (USD Million)

Table 27 Europe: New-born Screening, by End Users, 2018–2023 (USD Million)

Table 28 Western Europe: New-born Screening, by Technology, 2018–2023 (USD Million)

Table 29 Western Europe: New-born Screening, by Test type, 2018–2023 (USD Million)

Table 30 Western Europe: New-born Screening, by Products, 2018–2023 (USD Million)

Table 31 Western Europe: New-born Screening, by End Users, 2018–2023 (USD Million)

Table 32 Eastern Europe: New-born Screening, by Technology, 2018–2023 (USD Million)

Table 33 Eastern Europe New-born Screening, by Test type, 2018–2023 (USD Million)

Table 34 Eastern Europe: New-born Screening, by Products, 2018–2023 (USD Million)

Table 35 Eastern Europe: New-born Screening, by End Users, 2018–2023 (USD Million)

Table 36 Asia-Pacific: New-born Screening, by Technology, 2018–2023 (USD Million)

Table 37 Asia-Pacific: New-born Screening, by Test type, 2018–2023 (USD Million)

Table 38 Asia-Pacific: New-born Screening, by Products, 2018–2023 (USD Million)

Table 39 Asia-Pacific: New-born Screening, by End Users, 2018–2023 (USD Million)

Table 40 Middle East & Africa: New-born Screening, by Technology, 2018–2023 (USD Million)

Table 41 Middle East & Africa: New-born Screening, by Test type, 2018–2023 (USD Million)

Table 42 Middle East & Africa: New-born Screening, by Products, 2018–2023 (USD Million)

Table 43 Middle East & Africa: New-born Screening, by End Users, 2018–2023 (USD Million)



LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global New-born Screening

Figure 3 Segmentation Market Dynamics for Global New-born Screening

Figure 4 Global New-born Screening Share, by Technology, 2017



Figure 5 Global New-born Screening, by Test type, 2017

Figure 6 Global New-born Screening, by Products, 2017

Figure 7 Global New-born Screening, by End Users, 2017

Figure 8 Global New-born Screening Share, by Region, 2017

Figure 9 North America: New-born Screening Share, by Country, 2017

Figure 10 Europe: New-born Screening Share, by Country, 2017

Figure 11 Asia-Pacific: New-born Screening Share, by Country, 2017

Figure 12 Middle East & Africa: New-born Screening Share, by Country, 2017

Figure 13 Global New-born Screening: Company Share Analysis, 2017 (%)

Figure 14 AB Sciex LLC (A Subsidiary of Danaher Corporation): Key Financials

Figure 15 AB Sciex LLC (A Subsidiary of Danaher Corporation): Segmental Revenue

Figure 16 AB Sciex LLC (A Subsidiary of Danaher Corporation): Geographical Revenue

Figure 17 Perkinelmer, Inc.: Key Financials

Figure 18 Perkinelmer, Inc.: Segmental Revenue

Figure 19 Perkinelmer, Inc.: Geographical Revenue

Figure 20 Waters Corporation: Key Financials

Figure 21 Waters Corporation: Segmental Revenue

Figure 22 Waters Corporation: Geographical Revenue

Figure 23 Natus Medical Incorporated: Key Financials

Figure 24 Natus Medical Incorporated: Segmental Revenue

Figure 25 Natus Medical Incorporated: Geographical Revenue

Figure 26 Masimo Corporation: Key Financials

Figure 27 Masimo Corporation: Segmental Revenue

Figure 28 Masimo Corporation: Geographical Revenue

Figure 29 Agilent Technologies Inc.: Key Financials

Figure 30 Agilent Technologies Inc.: Segmental Revenue

Figure 31 Agilent Technologies Inc.: Geographical Revenue

Figure 32 Bio-Rad Laboratories, Inc.: Key Financials

Figure 33 Bio-Rad Laboratories, Inc.: Segmental Revenue

Figure 34 Bio-Rad Laboratories, Inc.: Geographical Revenue

Figure 35 Covidien PLC.: Key Financials

Figure 36 Covidien PLC.: Segmental Revenue

Figure 37 Covidien PLC.: Geographical Revenue

Figure 38 GE Healthcare (A Subsidiary of General Electric Company): Key Financials

Figure 39 GE Healthcare (A Subsidiary of General Electric Company): Segmental Revenue

Figure 42 GE Healthcare (A Subsidiary of General Electric Company): Geographical Revenue

Figure 43 Trivitron Healthcare: Key Financials

Figure 44 Trivitron Healthcare: Segmental Revenue

Figure 45 Trivitron Healthcare: Geographical Revenue

Figure 46 ZenTech S.A: Key Financials

Figure 47 ZenTech S.A: Segmental Revenue

Figure 48 ZenTech S.A: Geographical Revenue

Figure 49 Others: Key Financials

Figure 50 Others: Segmental Revenue

Figure 51 Others: Geographical Revenue